The administration of adagrasib, at a dose of 600 mg orally twice a day, has been investigated in the multi-cohort, phase I/II KRYSTAL-1 study (NCT03785249), in 110 patients with advanced solid tumors, including 79 NSCLC patients with KRAS G12C mutation, who had progressed after previous standard treatments. Here, KRAS is linked to non-small cell lung carcinoma.